IN VITRO, IN VIVO, ACOUSTIC CHARACTERIZATION--AEROSOMES

Information

  • Research Project
  • 2104058
  • ApplicationId
    2104058
  • Core Project Number
    R44CA062659
  • Full Project Number
    5R44CA062659-03
  • Serial Number
    62659
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1993 - 31 years ago
  • Project End Date
    9/29/1995 - 29 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1994 - 30 years ago
  • Budget End Date
    9/29/1995 - 29 years ago
  • Fiscal Year
    1994
  • Support Year
    3
  • Suffix
  • Award Notice Date
    9/8/1994 - 30 years ago
Organizations

IN VITRO, IN VIVO, ACOUSTIC CHARACTERIZATION--AEROSOMES

DESCRIPTION (Adapted from Applicant's Abstract): Diagnostic ultrasound potentially represents a billion dollar a year market worldwide. The applicants' specific aims and longterm objective involve the development of an efficient and low-cost ultrasound contrast agent with improved image sensitivity such that the applicants believe could become the industry standard for a variety of diagnostic procedures (i.e. hepatosplenic imaging, cardiac imaging and wall-motion studies, blood- pool imaging [hemangiomas], and vascular flow studies). The research methodology would involve critical in vitro, in vivo, and acoustic characterization studies to aid the applicant organization, ImaRx Pharmaceutical, in determining the potential for it's application. The implications of the research could provide a means for substantially reduced health-care costs with regard to diagnostic imaging as the use of Aerosomes with ultrasound potentially could become a high quality and reliable alternative to existing, more costly, diagnostic procedures (MRI, CT, etc.). This could become particularly beneficial for small community hospitals as well as third work health care concerns as Aerosomes with ultrasound could provide high quality, low cost diagnostic healthcare. Goals of Phase II would include: acoustic characterization; shelf life stability determination; conduct of detailed pharmacology and toxicology; conduct of detailed biodistribution studies, conduct of further imaging studies, and initiate planning of Phase I clinical trials.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    IMARX THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    782996045
  • Organization City
    TUCSON
  • Organization State
    AZ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    85719
  • Organization District
    UNITED STATES